South Korea Prepared To Kill North Korean Leader Kim Jong-Un If Necessary

Markets Benzinga

Disputes among neighbors are no rarity. However, this one is not your regular family feud over loud music or wrong trashcan use. In fact, its pretty much the opposite; its a quarrel over nuclear weapons something that certainly sounds like a 40-years-ago issue.

Continue Reading Below

South Korea has an elite military squad prepared to assassinate North Korean leader Kim Jong-un if necessary, the formers Defense Minister Han Min-koo said last Wednesday. If S. Korea see clear sings of a threat, it will "take action, the Minister explicated, adding this was part of a wider "Korea Massive Punishment and Retaliation" (KMPR) plan, launched right after its neighbors fifth nuclear test, less than 20 days ago.

Related Link: Kim Jong-Un Still Seeking Weapons That Work

The KMPR targets North Korean leadership, including its military headquarters, with a preemptive strike that includes teams of highly trained commandos and simultaneous missile attacks capable of precision strikes, in case of the North's nuclear attack on the South, the Korea Times article that initially covered the issue read.

Shares of the iShares MSCI South Korea Index Fund(ETF) (EWY) have gained more than 3.5 percent over the past five trading days. Over the same period, the DBX ETF Trust (DBKO), the Deutsche X-trackers MSCI South Korea Hedged Equity ETF, spiked more than 2 percent; the First Trust Exchange Traded AlphaDEX Fund II (FKO), or First Trust South Korea AlphaDEX Fund, almost 4 percent; and the WisdomTree Korea Hedged Equity Fund (DXKW) surged 3.7 percent.

Full ratings data available on Benzinga Pro.

Continue Reading Below

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above.

2016 Benzinga does not provide investment advice. All rights reserved.